193 related articles for article (PubMed ID: 38179430)
1. Enhanced EPR effects by tumour stromal cell mimicking nanoplatform on invasive pituitary adenoma.
Ma J; Wei Y; Zhang X; Lin L; Bao Y; Cao H; Chen H; Yu J; Yang J; Zhang Y; Lan H; Li X; Qiong H; Yang D; Yu Y; Chen J; Zhang C; Liu L; Chen L; Zhan R; Liu F
Mater Today Bio; 2024 Feb; 24():100895. PubMed ID: 38179430
[TBL] [Abstract][Full Text] [Related]
2. Tumor microenvironment targeting system for glioma treatment via fusion cell membrane coating nanotechnology.
Ma J; Dai L; Yu J; Cao H; Bao Y; Hu J; Zhou L; Yang J; Sofia A; Chen H; Wu F; Xie Z; Qian W; Zhan R
Biomaterials; 2023 Apr; 295():122026. PubMed ID: 36731366
[TBL] [Abstract][Full Text] [Related]
3. Delivery of polymeric nanostars for molecular imaging and endoradiotherapy through the enhanced permeability and retention (EPR) effect.
Goos JACM; Cho A; Carter LM; Dilling TR; Davydova M; Mandleywala K; Puttick S; Gupta A; Price WS; Quinn JF; Whittaker MR; Lewis JS; Davis TP
Theranostics; 2020; 10(2):567-584. PubMed ID: 31903138
[TBL] [Abstract][Full Text] [Related]
4. PLGA nanoparticles containing various anticancer agents and tumour delivery by EPR effect.
Acharya S; Sahoo SK
Adv Drug Deliv Rev; 2011 Mar; 63(3):170-83. PubMed ID: 20965219
[TBL] [Abstract][Full Text] [Related]
5. Blood vessel hyperpermeability and pathophysiology in human tumour xenograft models of breast cancer: a comparison of ectopic and orthotopic tumours.
Ho KS; Poon PC; Owen SC; Shoichet MS
BMC Cancer; 2012 Dec; 12():579. PubMed ID: 23217114
[TBL] [Abstract][Full Text] [Related]
6. Nanoparticles' interactions with vasculature in diseases.
Tee JK; Yip LX; Tan ES; Santitewagun S; Prasath A; Ke PC; Ho HK; Leong DT
Chem Soc Rev; 2019 Oct; 48(21):5381-5407. PubMed ID: 31495856
[TBL] [Abstract][Full Text] [Related]
7. The application of nanoparticles in cancer immunotherapy: Targeting tumor microenvironment.
Yang M; Li J; Gu P; Fan X
Bioact Mater; 2021 Jul; 6(7):1973-1987. PubMed ID: 33426371
[TBL] [Abstract][Full Text] [Related]
8. From Passive Targeting to Personalized Nanomedicine: Multidimensional Insights on Nanoparticles' Interaction with the Tumor Microenvironment.
Sebak AA; El-Shenawy BM; El-Safy S; El-Shazly M
Curr Pharm Biotechnol; 2021; 22(11):1444-1465. PubMed ID: 33308126
[TBL] [Abstract][Full Text] [Related]
9. Tumor microenvironment-responsive versatile "Trojan horse" theranostic nanoplatform for magnetic resonance imaging-guided multimodal synergistic antitumor treatment.
Huang Q; Pan Y; Wang M; Liu Z; Chen H; Wang J; Zhao Z; Zhang Y
Acta Biomater; 2022 Jul; 147():270-286. PubMed ID: 35595202
[TBL] [Abstract][Full Text] [Related]
10. Renewing an old interest: Pituitary folliculostellate cells.
Le Tissier PR; Mollard P
J Neuroendocrinol; 2021 Nov; 33(11):e13053. PubMed ID: 34734454
[TBL] [Abstract][Full Text] [Related]
11. Cell membrane-based nanoparticles: a new biomimetic platform for tumor diagnosis and treatment.
Li R; He Y; Zhang S; Qin J; Wang J
Acta Pharm Sin B; 2018 Jan; 8(1):14-22. PubMed ID: 29872619
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical study of folliculostellate cells in pituitary lesions.
Nishioka H; Llena JF; Hirano A
Endocr Pathol; 1991 Sep; 2(3):155-160. PubMed ID: 32357644
[TBL] [Abstract][Full Text] [Related]
13. Alliance with EPR Effect: Combined Strategies to Improve the EPR Effect in the Tumor Microenvironment.
Park J; Choi Y; Chang H; Um W; Ryu JH; Kwon IC
Theranostics; 2019; 9(26):8073-8090. PubMed ID: 31754382
[TBL] [Abstract][Full Text] [Related]
14. A light-controllable specific drug delivery nanoplatform for targeted bimodal imaging-guided photothermal/chemo synergistic cancer therapy.
Guo Y; Wang XY; Chen YL; Liu FQ; Tan MX; Ao M; Yu JH; Ran HT; Wang ZX
Acta Biomater; 2018 Oct; 80():308-326. PubMed ID: 30240955
[TBL] [Abstract][Full Text] [Related]
15. Distinctive actions of connexin 46 and connexin 50 in anterior pituitary folliculostellate cells.
Vitale ML; Garcia CJ; Akpovi CD; Pelletier RM
PLoS One; 2017; 12(7):e0182495. PubMed ID: 28759642
[TBL] [Abstract][Full Text] [Related]
16. Reappraisal of anticancer nanomedicine design criteria in three types of preclinical cancer models for better clinical translation.
Luan X; Yuan H; Song Y; Hu H; Wen B; He M; Zhang H; Li Y; Li F; Shu P; Burnett JP; Truchan N; Palmisano M; Pai MP; Zhou S; Gao W; Sun D
Biomaterials; 2021 Aug; 275():120910. PubMed ID: 34144373
[TBL] [Abstract][Full Text] [Related]
17. Rat anterior pituitary folliculostellate cells are targets of interleukin-1beta and a major source of intrapituitary follistatin.
Bilezikjian LM; Leal AM; Blount AL; Corrigan AZ; Turnbull AV; Vale WW
Endocrinology; 2003 Feb; 144(2):732-40. PubMed ID: 12538636
[TBL] [Abstract][Full Text] [Related]
18. Biomimetic theranostic nanoparticles for effective anticancer therapy and MRI imaging.
Bigaj-Józefowska MJ; Coy E; Załęski K; Zalewski T; Grabowska M; Jaskot K; Perrigue P; Mrówczyński R; Grześkowiak BF
J Photochem Photobiol B; 2023 Dec; 249():112813. PubMed ID: 37977004
[TBL] [Abstract][Full Text] [Related]
19. Biphasic Effect of Basic Fibroblast Growth Factor on Anterior Pituitary Folliculostellate TtT/GF Cell Coupling, and Connexin 43 Expression and Phosphorylation.
Vitale ML; Barry A
J Neuroendocrinol; 2015 Oct; 27(10):787-801. PubMed ID: 26265106
[TBL] [Abstract][Full Text] [Related]
20. Strategies to enhance drug delivery to solid tumors by harnessing the EPR effects and alternative targeting mechanisms.
Zi Y; Yang K; He J; Wu Z; Liu J; Zhang W
Adv Drug Deliv Rev; 2022 Sep; 188():114449. PubMed ID: 35835353
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
